I. Basic Information
Item | Details
English Name | Atomoxetine hydrochloride; Strattera (trade name)
Chinese Name | Atomoxetine Hydrochloride
CAS Number | 82248-59-7 (hydrochloride); 83015-26-3 (free base)
Chemical Name | (R)-N-methyl-3-phenyl-3-(o-tolyloxy)propan-1-amine hydrochloride
Molecular Formula | Free base C₁₇H₂₁NO; Hydrochloride C₁₇H₂₁NO・HCl
Molecular Weight | Free base 255.36; Hydrochloride 291.82
Target | Norepinephrine transporter (NET), selective norepinephrine reuptake inhibitor
Developer | Eli Lilly
Market Launch Date | November 2002 (US FDA); October 2007 (China NMPA)
Dosage Forms and Strengths | Capsules: 10mg, 18mg, 25mg, 40mg, 60mg (calculated as atomoxetine)
II. Physicochemical Properties
Parameter | Data (hydrochloride)
Appearance | White to off-white crystalline powder
Solubility | Easily soluble in water (approximately 27 mg/mL, 25℃), methanol, ethanol, slightly soluble in acetone, insoluble in diethyl ether
Dissociation Constant (pKa) | 10.1 (amino group) (measured value)
Melting Point | 179-181℃ (decomposition)
Stability | Stable for 36 months at 25℃/60% RH, stored in a sealed, cool and dry place (20-25℃), avoid high temperature, light and moisture
Chiral Characteristics | Contains 1 chiral center (phenylpropanamine position), single R-configuration (active configuration), optical purity >99.5%
Partition Coefficient (logP) 3.9 (Free base, predicted value)
III. Mechanism of Action
Atomoxetine hydrochloride works by highly selectively inhibiting the norepinephrine transporter (NET) on the presynaptic membrane, reducing norepinephrine reuptake, and increasing norepinephrine concentration in the synaptic cleft. This improves neurotransmission in the prefrontal cortex of the brain. Key characteristics:
It has significantly higher selectivity for NET than for serotonin (5-HT) and dopamine (DA) transporters, without the dopamine reuptake inhibition effect of central nervous system stimulants, and is not addictive.
The prefrontal cortex is a key region for regulating attention, impulse control, and executive function. Increased norepinephrine concentration can significantly improve inattention, hyperactivity, and impulsivity symptoms in ADHD patients.
It has a slow onset of action, usually requiring 2-4 weeks to achieve optimal efficacy, and requires regular medication for maintenance.